Holen Sie sich die Stockscreener-App
1.82
0.00%
0.00
Handel nachbörslich:
1.75
-0.07
-3.85%
Schlusskurs vom Vortag:
$1.82
Offen:
$1.83
24-Stunden-Volumen:
138.02K
Relative Volume:
0.87
Marktkapitalisierung:
$101.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.38M
KGV:
-4.6667
EPS:
-0.39
Netto-Cashflow:
$-25.19M
1W Leistung:
+2.25%
1M Leistung:
+16.67%
6M Leistung:
+179.61%
1J Leistung:
+30.00%
1-Tages-Spanne:
$1.66
$1.90
1-Wochen-Bereich:
$1.66
$2.05
52-Wochen-Spanne:
$0.51
$2.86
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Firmenname
Connect Biopharma Holdings Ltd
Sektor
Branche
Telefon
858-727-1040
Adresse
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Vergleichen Sie CNTB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
1.82 | 101.43M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | Jefferies | Buy |
| 2021-04-13 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-13 | Eingeleitet | SVB Leerink | Outperform |
Connect Biopharma Holdings Ltd Aktie (CNTB) Neueste Nachrichten
Connect Biopharma's (CNTB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Severe Asthma Pipeline 2025: Therapies Under Investigation, - openPR.com
Connect Biopharma (NASDAQ:CNTB) Stock Price Up 7.4%Still a Buy? - MarketBeat
October 2025's Promising Penny Stocks To Consider - Yahoo Finance
Short Interest in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Drops By 53.6% - MarketBeat
H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target - Investing.com Nigeria
507mL Lung Function Improvement: Connect Bio's New Asthma Drug Shows Remarkable Results in High-Risk Patients - Stock Titan
James Huang to join CASI Pharmaceuticals board as independent director By Investing.com - Investing.com Australia
CASI Pharmaceuticals Appoints James Huang to Board of Directors - ACCESS Newswire
35-Year Biotech Veteran James Huang Joins CASI Pharma Board as Company Advances CID-103 Program - Stock Titan
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma - Barchart.com
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, - openPR.com
FY2025 EPS Estimate for Connect Biopharma Lowered by Analyst - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Drop in Short Interest - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Up 204.8% in August - MarketBeat
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Increase in Short Interest - Defense World
Connect Biopharma Announces Poster Presentations of Rademikibart at the European Respiratory Society Congress 2025 - Quiver Quantitative
New Asthma Treatment Data: Connect Biopharma's Rademikibart Shows Impact on FEV1 in Type 2 Asthma Trial - Stock Titan
Connect Biopharma completes termination of its American depositary receipt program and directly lists its ordinary shares on Nasdaq - MarketScreener
Connect Biopharma Ends ADR Program, Moves to Direct Nasdaq Listing; Shares Up Premarket - MarketScreener
Connect Biopharma Completes Termination of its American - GlobeNewswire
Biotech Connect Biopharma Completes Strategic Shift to Direct Nasdaq Listing for U.S. Growth - Stock Titan
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq - Yahoo Finance
COPD Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma - Barchart.com
3 Penny Stocks To Watch With Market Caps Over $100M - simplywall.st
Connect Biopharma (CNTB) Expected to Announce Quarterly Earnings on Friday - Defense World
Connect Biopharma Holdings Limited to Participate in Upcoming Healthcare Conferences - Quiver Quantitative
Clinical-Stage Biotech Connect Biopharma Announces Key September Investor Conference Appearances - Stock Titan
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - Yahoo Finance
Connect Biopharma (NASDAQ:CNTB) Upgraded to Hold at Wall Street Zen - Defense World
Connect Biopharma Advances Clinical Trials and Nasdaq Listing - AInvest
Connect Biopharma Posts Q2 Revenue Drop - AOL.com
Q3 Earnings Estimate for CNTB Issued By Leerink Partnrs - Defense World
HC Wainwright Cuts Earnings Estimates for Connect Biopharma - Defense World
Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Yahoo Finance
Connect Biopharma Reports Q2 Revenue Drop of 99.2% to $48,000, R&D Spending Increases 65.6% to $8.8mln - AInvest
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide - Yahoo Finance
Connect Biopharma Holdings Ltd SEC 10-Q Report - TradingView
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight - openPR.com
Connect Biopharma Holdings Limited shares rise 5.63% after-hours following Jazz Pharmaceuticals' FDA approval of Modeyso. - AInvest
Connect Biopharma Shares Rise on Plan to End ADR Program and Directly List on Nasdaq - MSN
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Research Analysts Set Expectations for CNTB Q2 Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded at Northland Capmk - Defense World
Q2 Earnings Estimate for CNTB Issued By Northland Capmk - Defense World
Finanzdaten der Connect Biopharma Holdings Ltd-Aktie (CNTB)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):